US equities
|
NVDA
$239.76
▲+2.48%
SPCX
$169.32
▲+6.52%
MU
$1,062.64
▼-1.14%
TSLA
$379.82
▲+2.49%
SNDK
$1,702.76
▼-1.00%
MSFT
$527.85
▲+1.99%
INTC
$116.15
▼-2.66%
META
$742.55
▲+1.99%
NVDA
$239.76
▲+2.48%
SPCX
$169.32
▲+6.52%
MU
$1,062.64
▼-1.14%
TSLA
$379.82
▲+2.49%
SNDK
$1,702.76
▼-1.00%
MSFT
$527.85
▲+1.99%
INTC
$116.15
▼-2.66%
META
$742.55
▲+1.99%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
25.18
+0.02 (+0.06%)
Delayed Quote
Updated: 3:43 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
April 27, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
April 22, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate
↗
April 14, 2026
Arcutis Biotherapeutics (ARQT) combines strong earnings growth with a bullish technical setup, presenting a potential breakout opportunity for momentum investors.
Via
Chartmill
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook
↗
February 25, 2026
Via
Chartmill
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup
↗
February 13, 2026
Via
Chartmill
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup
↗
February 11, 2026
Via
Chartmill
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
↗
April 08, 2026
Focused on innovative dermatology treatments, this biopharma firm reported a notable insider sale amid a strong year for its shares.
Via
The Motley Fool
Topics
Regulatory Compliance
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 07, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
March 28, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
March 18, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
March 10, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
March 05, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
March 03, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis (ARQT) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Arcutis (ARQT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
February 24, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit
↗
February 06, 2026
Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis.
Via
The Motley Fool
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
February 02, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
January 26, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
January 21, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
January 12, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics (NASDAQ:ARQT) Combines High-Growth Momentum with Bullish Technical Setup
↗
December 30, 2025
Arcutis Biotherapeutics (ARQT) combines strong revenue growth & earnings momentum with a bullish technical chart setup, signaling a potential breakout opportunity.
Via
Chartmill
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares
↗
December 23, 2025
Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline.
Via
The Motley Fool
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
↗
December 23, 2025
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.
Via
The Motley Fool
Topics
Regulatory Compliance
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
December 22, 2025
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...
Via
MarketMinute
Topics
ETFs
Economy
Intellectual Property
This Biotech Stock Could Cure Your Portfolio's Pain
↗
December 14, 2025
A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.
Via
The Motley Fool
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum
↗
December 11, 2025
Arcuitis Biotherapeutics (ARQT) exemplifies a high-growth momentum stock in a confirmed technical uptrend, blending strong fundamentals with a robust price structure.
Via
Chartmill
Why Shares in Arcutis Biotherapeutics Surged Again This Week
↗
November 21, 2025
The company continues to receive good news from the Food and Drug Administration.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 19, 2025
Via
Benzinga
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
November 17, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
